HONG KONG – Shanghai Green Valley (Group) Co. Ltd. is gearing up to file for approval in China later this year after its sodium oligomannurarate (GV-971) capsules significantly improved cognition among patients with mild to moderate Alzheimer's disease (AD) in phase III trials.
HONG KONG – The China National Drug Administration (CNDA) has approved the first domestically developed HIV drug. Known as Aikening (albuvirtide for injection), the novel drug was developed by Frontier Biotechnologies Inc., of Nanjing, to treat HIV-1 infection.
HONG KONG – The China National Drug Administration (CNDA) has approved the first domestically developed HIV drug. Known as Aikening (albuvirtide for injection), the novel drug was developed by Frontier Biotechnologies Inc., of Nanjing, to treat HIV-1 infection.
HONG KONG – Shenzhen-listed Harbin Gloria Pharmaceuticals Co. Ltd. plans to acquire a major stake in insulin maker Hefei Tianmai Biotechnology Development Co. Ltd. (HTBT) for ¥4 billion (US$600 million). Gloria is after HTBT's lead product, an oral insulin being co-developed with Israeli company Oramed Pharmaceuticals Inc.
HONG KONG – Two Chinese biopharma firms, Shanghai Junshi Biosciences Co. Ltd. and Hong Kong-listed CSPC Pharmaceutical Group Ltd. will join hands in developing a combination therapy for breast cancer. Under the agreement, Junshi will provide its PD-1 antibody candidate, JS-001, to be used in combination with CSPC's newly approved paclitaxel for injection (albumin-bound). The two companies will jointly develop, register and commercialize the therapy in greater China.
HONG KONG – Shenzhen-listed Harbin Gloria Pharmaceuticals Co. Ltd. plans to acquire a major stake in insulin maker Hefei Tianmai Biotechnology Development Co. Ltd. (HTBT) for ¥4 billion (US$600 million). Gloria is after HTBT's lead product, an oral insulin being co-developed with Israeli company Oramed Pharmaceuticals Inc.
HONG KONG – Two Chinese biopharma firms, Shanghai Junshi Biosciences Co. Ltd. and Hong Kong-listed CSPC Pharmaceutical Group Ltd. will join hands in developing a combination therapy for breast cancer. Under the agreement, Junshi will provide its PD-1 antibody candidate, JS-001, to be used in combination with CSPC's newly approved paclitaxel for injection (albumin-bound). The two companies will jointly develop, register and commercialize the therapy in greater China.
HONG KONG – South Korean company Alteogen Inc. is working with its U.S. partner, Lynkogen Inc., of New Jersey, to develop novel GLP-1 mimetic and alpha-1 antitrypsin (A1AT) fusion proteins for the treatment of nonalcoholic steatohepatitis (NASH) and metabolic diseases. Clinical trials could begin in two years' time.
HONG KONG – Hangzhou, China-based Adlai Nortye Biopharma Co. Ltd. said Tuesday it partnered with Novartis AG to obtain the worldwide rights to BKM-120 (buparlisib), a selective PI3K inhibitor, to treat head and neck cancer, adding one more lead product to the Chinese company's oncology pipeline.
